Research opportunity information may be provided on behalf of an external organization. Please refer to the contact information within each listing to identify the contact for questions or comments.
A new study for Ocrevus and Kesimpta users!
This research aims to understand changes in MS symptoms between doses for people with MS who are treated with ocrelizumab (Ocrevus) or ofatumumab (Kesimpta). We’re conducting this study with the pharmaceutical company Novartis and their consultant STATLOG Inc.
Participation involves completing a set of questionnaires at enrollment, and before and after your next two treatment doses. Participants will be compensated $50 for each set of questionnaires that is completed, up to $250 total.
You may be eligible for this study if you:
- live in the United States
- have been diagnosed with relapsing MS, secondary progressive MS, or clinically isolated syndrome (CIS)
- are currently being treated with either Kesimpta or Ocrevus
- Kesimpta users: treatment start was at least 6 months ago
- Ocrevus users: treatment start was at least 1 year ago, and most recent dose was at least 3 months ago
If you are interested in participating in this study, please email us at info@iconquerms.org and we will send you further information. If you don’t meet the eligibility criteria now but expect to do so in the future, please get in touch to let us know.
Have you ever applied for Social Security benefits? Please share your experiences!
Sandy Johnson, a PhD candidate at Walden University, is conducting research on the experience of women with MS in obtaining benefits from the Social Security Administration. She is seeking 20 volunteers to conduct a confidential phone interview lasting up to an hour.
You may be eligible if you:
- Are born female
- Are 25-61 years of age
- Have been diagnosed with MS
- Live in the US
- Have applied for Social Security benefits due to cognitive issues (problems with thinking or memory) that caused you to leave the workforce
If you meet these criteria and would like to schedule an interview, please contact Sandy Johnson at 404-804-8626 or at Sandy.johnson@waldenu.edu. You can also complete a pre-screening survey at https://forms.office.com/r/E8r7fDWKY7 if you’d like to learn more and confirm your eligibility.
Study participants recently spoke about their experiences taking part in the TEAAMS study on Brain Chat with the Nerdy Neurologist and RealTalk MS. Tune in and listen today!
A new topic for the Our Questions Have Power program!
When it comes to MS symptoms and how to manage them, what questions are most important to you? What symptom-related topics do you wish researchers were studying? Your questions are valuable and we invite you to share them through the Our Questions Have Power program on the iConquerMS website.
The Our Questions Have Power program was launched in March 2021 with an initial focus on COVID-19. Questions submitted by iConquerMS members have helped shape the COVER-MS vaccination study and are being shared with the research community to guide other efforts.
We’re now extending Our Questions Have Power to include a second topic: MS symptoms and their management and treatment. As before, you’re invited to share questions on this topic that you think should be studied and to vote on questions submitted by other iConquerMS members. We’ll share these questions with people affected by MS, researchers, healthcare professionals, advocates, and funders – and, together, we’ll work to launch research studies to answer those questions.
It’s easy to share your ideas and input in Our Questions Have Power!
